Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
• Claims to be issued cover all commercial dosage strengths of Rubraca®
• This will be the 10th Orange Book-listed
patent for Rubraca
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 8, 2018--
Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has
received a Notice of Allowance from the United States Patent and
Trademark Office in United States Patent Application 14/828,065 with
claims directed to high dosage strength ruc...
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 7, 2018--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.
Mahaffy, Chief Executive Officer and President, will present at the
Barclays Global Healthcare Conference on Thursday, March 15, 2018 at
8:00 AM Eastern Time. The conference will be held at the Loews Miami
Beach Hotel in Miami.
A live webcast of the presentation can be accessed through the investor
relations section of the C...
First full year of Rubraca® (rucaparib)
U.S. sales totaled $55.5M, including $17.0M for the fourth quarter of
2017, with limited third-line BRCA-mutant ovarian cancer treatment
U.S. maintenance treatment indication under review, with April 6,
2018 PDUFA date
CHMP positive trend vote communicated for limited treatment
indication; formal CHMP vote anticipated in March 2018
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.